Glioma

May is Brain Cancer Awareness Month.

Younger patients with diffuse midline glioma experienced prolonged clinical improvement after receiving an investigational chimeric antigen receptor T-cell therapy, study results demonstrated.

National Cancer Institute announced the launch of a program that offers molecular characterization of childhood cancers.

Researchers reported common causes of death and end-of-life care experiences among patients with intracranial high-grade gliomas in a retrospective observational study published in Neurology.

The FDA awarded 11 grants worth more than $25 million to fund clinical trials of medical products intended to treat patients with rare diseases.

The FDA granted orphan drug designation to LP-184 for the treatment of glioblastoma multiforme and other malignant gliomas.

Neuro-oncologists must grapple daily with precarious brain tumors that are often masked by common symptoms such as a headache or seizure.

The FDA granted orphan drug designation to iniparib for treatment of malignant glioma, according to the agent’s manufacturer.

Patients with glioma who completed the 8-week GLioma Atkins-based Diet experienced “meaningful” ketonuria and significant systemic and cerebral metabolic changes, according to results from a small study published in Neurology.

Olaparib monotherapy appeared well-tolerated and demonstrated evidence of antitumor activity among patients with heavily pretreated isocitrate dehydrogenase-mutant high-grade glioma, according to results of the phase 2 OLAGLI study.